Abstract P3-12-05: Real-world use of sacituzumab govitecan (SG) in the management of metastatic triple-negative breast cancer (mTNBC) through a Canadian Patient Support Program (PSP)
Notice bibliographique
Résumé
Abstract Background: In the ASCENT trial, SG demonstrated significant survival improvements compared to single agent chemotherapy in previously treated mTNBC. Based on these findings, SG was approved by the FDA and Health Canada in 2021 for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received ≥2 prior systemic therapies, at least one of them in the metastatic setting. Here, we report the first study to characterize the real-world use of SG in patients with previously treated mTNBC in Canada. Methods: This was a cohort study of Canadian patients with unresectable locally advanced or metastatic TNBC who received at least one dose of SG between November 2021 and December 2023 via the Gilead Sciences Canada’s Patient Support Program post-approval. Demographic and clinical data were collected as part of PSP enrollment. Patients were followed up until the end of treatment, defined as death, SG discontinuation or lost to follow up, whichever occurred the first. The Kaplan-Meier method was used to estimate treatment duration. Results: A total of 453 patients were identified with a median age of 58 years and mean weight of 71 kg. 245 patients (54%) were primarily treated at a cancer centre and 208 patients (46%) were treated at private infusion Innomar Clinics location. Patients were enrolled in the PSP to receive SG in second-line (2L, 29%); 3L (43%) or 4L+ (28%). The median treatment duration was 4.2 months (95% CI 3.7-4.9). The median dose at treatment initiation was 10.0 mg/kg (IQR, 10.0-10.0) and 355 patients (78%) experienced at least one dose delay and 250 patients (55%) experienced at least one dose reduction. Treatment delay and dose reduction were due to any reason. Among the 323 patients who discontinued treatment, 197 (61%) discontinued due to physician decision in the context of change in patient condition or disease progression. Patients aged < 65 years at enrollment had a median treatment duration of 4.4 months (95% CI 3.7-5.1), whereas those aged ≥ 65 years had a median treatment duration of 3.8 months (95% CI 3.0-5.3). The median treatment duration of SG was 3.7 months (95% CI 3.0-5.3), 4.7 months (95% CI 3.9-5.6), and 3.5 months (95% CI 2.8-4.9) when used in 2L, 3L, and 4L+, respectively with a logrank p=0.2. Conclusions: This study reports real-world SG treatment patterns that are generally consistent with those of the ASCENT trial. These findings support the clinical benefit of SG demonstrated by existing clinical trial data. Potential limitations include the limited capacity of the PSP, the presence of unmeasured confounding, purposive sampling during PSP enrollment, and lack of data linkage. Citation Format: Pierre-Luc Tanguay, Meng Wang, Winson Y. Cheung, A. Anna Cumaraswamy, Philip Q. Ding. Real-world use of sacituzumab govitecan (SG) in the management of metastatic triple-negative breast cancer (mTNBC) through a Canadian Patient Support Program (PSP) [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr P3-12-05.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
Comment cette classification a été obtenuedéplier
Prédiction distillée sur la base complète
Imitation des enseignantsNi prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.
Scores Codex et Gemma par catégorie
| Catégorie | Codex | Gemma |
|---|---|---|
| Métarecherche | 0,002 | 0,000 |
| Méta-épidémiologie (sens strict) | 0,000 | 0,000 |
| Méta-épidémiologie (sens large) | 0,001 | 0,000 |
| Bibliométrie | 0,001 | 0,003 |
| Études des sciences et des technologies | 0,000 | 0,001 |
| Communication savante | 0,000 | 0,000 |
| Science ouverte | 0,001 | 0,000 |
| Intégrité de la recherche | 0,000 | 0,001 |
| Charge utile insuffisante (le modèle a refusé de juger) | 0,001 | 0,000 |
Scores machine (provisoires)
Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.
Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.
score_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découleClassification
machine, non validéePrédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.
Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».